chartexchange

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

GlobeNewswire Inc. | Oct 14, 2026 2:00 AM EDT

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026.

Read original article